quinoxalines has been researched along with Optic Neuropathy, Ischemic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrison, AR; Lee, MS; McLoon, LK; Saylor, M | 1 |
| Aktas, Z; Akyürek, N; Göçün, PU; Gurelik, G; Hasanreisoğlu, B; Onol, M | 1 |
| Avraham-Lubin, BC; Cohen, Y; Dadon-Bar-El, S; Dratviman-Storobinsky, O; Goldenberg-Cohen, N; Hasanreisoglu, M; Weinberger, D | 1 |
| Fazzone, HE; Kupersmith, MJ; Leibmann, J | 1 |
| Goff, MJ; Kerrison, JB | 1 |
| Lüdtke, H; Wilhelm, B; Wilhelm, H | 1 |
| Alcala, SR; Danylkova, NO; McLoon, LK; Pomeranz, HD | 1 |
| Aktaş, Z; Akyürek, N; Gürelik, G; Hasanreisoğlu, B; Onol, M | 1 |
1 review(s) available for quinoxalines and Optic Neuropathy, Ischemic
| Article | Year |
|---|---|
Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Humans; Neuroprotective Agents; Optic Neuropathy, Ischemic; Quinoxalines; Retina; Retinal Diseases; Vitreous Body | 2009 |
1 trial(s) available for quinoxalines and Optic Neuropathy, Ischemic
| Article | Year |
|---|---|
Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.
Topics: Acute Disease; Aged; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Optic Neuropathy, Ischemic; Quinoxalines; Time Factors; Treatment Outcome; Vision Disorders; Visual Acuity; Visual Fields | 2006 |
6 other study(ies) available for quinoxalines and Optic Neuropathy, Ischemic
| Article | Year |
|---|---|
Matrix metalloproteinase-9 expression in retinal ganglion cell layer and effect of topically applied brimonidine tartrate 0.2% therapy on this expression in an endothelin-1-induced optic nerve ischemia model.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Gene Expression Regulation, Enzymologic; In Situ Nick-End Labeling; Infusion Pumps; Intraocular Pressure; Matrix Metalloproteinase 9; Optic Neuropathy, Ischemic; Quinoxalines; Rabbits; Retinal Ganglion Cells | 2010 |
Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy.
Topics: Animals; Brimonidine Tartrate; Disease Models, Animal; Eye Proteins; Fluorescent Antibody Technique, Indirect; Gene Expression; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Heme Oxygenase-1; Hypoxia-Inducible Factor 1, alpha Subunit; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factors; Neuroprotective Agents; Nitric Oxide Synthase Type III; Optic Neuropathy, Ischemic; Oxidative Stress; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, TIE-2; Retinal Ganglion Cells; Retinal Neovascularization; Serpins; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A | 2009 |
Does topical brimonidine tartrate help NAION?
Topics: Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Color Vision Defects; Humans; Ophthalmic Solutions; Optic Neuropathy, Ischemic; Quinoxalines; Retrospective Studies; Treatment Failure; Vision Disorders; Visual Acuity | 2003 |
Bilateral simultaneous anterior ischemic optic neuropathy in a young, healthy man.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Brimonidine Tartrate; Drug Therapy, Combination; Humans; Intraocular Pressure; Male; Optic Neuropathy, Ischemic; Quinoxalines; Visual Acuity; Visual Field Tests; Visual Fields | 2003 |
Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy.
Topics: Adrenergic alpha-Agonists; Animals; Axons; Benzoxazines; Brimonidine Tartrate; Cell Survival; Coloring Agents; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Neuroprotective Agents; Ophthalmic Solutions; Optic Neuropathy, Ischemic; Oxazines; Quinoxalines; Rats; Rats, Long-Evans; Retinal Ganglion Cells | 2007 |
Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Endothelin-1; Infusion Pumps, Implantable; Neuroprotective Agents; Optic Neuropathy, Ischemic; Quinoxalines; Rabbits; Retina; Retinal Ganglion Cells | 2007 |